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ABSTRACT (250 words)  38 
Objective: 39 
To date few industry-independent studies were conducted to compare the relative costs and 40 
benefits of drugs to treat MRSA infection. We performed a stochastic cost-effectiveness 41 
analysis comparing two treatment strategies -- linezolid versus trimethoprim-42 
sulfamethoxazole plus rifampicin -- for the treatment of MRSA infection. 43 
Methods: 44 
We used cost and effectiveness data from a previously conducted clinical trial, 45 
complementing with data from published literature, to compare the two regimens from a 46 
health-care system perspective. Effectiveness was expressed in terms of quality-adjusted life 47 
years (QALYs). Several sensitivity analyses were performed using Monte Carlo simulation, to 48 
measure the effect of potential parameter changes on the base-case model results, including 49 
potential differences related to type of infection and drug toxicity. 50 
Results:  51 
MRSA treatment with trimethoprim-sulfamethoxazole plus rifampicin and linezolid were 52 
found to cost on average 160€ and 2877€ per QALY gained, respectively. Treatment with 53 
trimethoprim-sulfamethoxazole plus rifampicin was found to be more cost-effective than 54 
linezolid in the base case and remained dominant over linezolid in most alternative 55 
scenarios, including different types of MRSA infection and potential disadvantages in terms 56 
of toxicity. With a willingness-to-pay threshold of 0€, 50’000€ and 200’000€ per QALY 57 
gained, trimethoprim-sulfamethoxazole plus rifampicin was dominant in 98%, 94% and 74% 58 
of model iterations. A 95% discount on the current purchasing price of linezolid would be 59 
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needed when it goes off-patent for it to represent better value for money compared to 60 
trimethoprim-sulfamethoxazole plus rifampicin.  61 
Conclusions: 62 
Combined treatment of trimethoprim-sulfamethoxazole plus rifampicin is more cost-63 
effective than linezolid in the treatment of MRSA infection. 64 
 65 
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INTRODUCTION 66 
Invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA) represent a 67 
therapeutic challenge. The treatment most frequently recommended is a prolonged course 68 
of parenteral vancomycin or daptomycin [1]. Alternative treatment regimens with oral 69 
antibiotics (e.g. linezolid [LZD]) have been proposed [2, 3]. The use of older drugs such as 70 
trimethoprim-sulfamethoxazole (TMP-SMX), combined with rifampicin (RMP) may represent 71 
a particularly interesting treatment alternative [1, 4, 5]. 72 
We previously performed a randomized, non-inferiority trial to compare the efficacy and 73 
safety of therapy with TMP-SMX plus RMP versus LZD to treat MRSA infection [6]. The 74 
principal findings of the study were: (i) compared with LZD, the combination of TMP-SMX 75 
plus RMP was non-inferior for the treatment of MRSA infection; (ii) there was no difference 76 
between the studied drugs in terms of total adverse events (AE), serious adverse events 77 
(SAE) or adverse drug reactions (ADR) [6]. Moreover, as TMP-SMX and RMP are available as 78 
generic agents, this regimen may offer a substantial cost advantage over other agents such 79 
as LZD and daptomycin [7]. As the launch of generic LZD has recently been postponed in 80 
several countries and novel oxazolidinone agents (e.g. tedizolid) will be patent-protected 81 
against generic erosion for many years, the off-patent combination of TMP-SMX plus RMP 82 
seems to be an attractive alternative oral treatment option for MRSA infection, though still 83 
underused because of safety concerns. However, this combination therapy may generate 84 
substantial indirect costs due to rare, but costly severe ADRs. For all these reasons, we 85 
performed a cost-effectiveness analysis using data from our randomized controlled trial 86 
(RCT) and other sources to examine the economic impact of these treatment regimens from 87 
the perspective of the healthcare system.  88 
 89 
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METHODS 90 
We constructed a stochastic decision tree model from a Swiss health-care system 91 
perspective, using TreeAge Pro 2015 (TreeAge Software, Williamstown, Massachusetts, 92 
USA). The model was developed using data of the previously published RCT comparing TMP-93 
SMX plus RMP to LZD for the treatment of any type of MRSA infection (Figure 1). This trial 94 
was an investigator-initiated, open-label, single-centre RCT to evaluate the efficacy of a 95 
combination of TMP-SMX (160/800 mg thrice daily) plus RMP (600 mg once daily) versus LZD 96 
(600 mg twice daily) in 150 patients (allocation ratio 1:1) requiring antibiotic therapy for 97 
MRSA infection at the Geneva University Hospitals. Patients who were treated for ≥72 h 98 
prior to study inclusion with antimicrobials active against MRSA (mostly vancomycin) were 99 
excluded.  We included all types of MRSA infection except chronic MRSA osteomyelitis 100 
without surgical debridement, a superinfected indwelling foreign body kept in place, severe 101 
sepsis or septic shock due to MRSA bacteraemia, and left-sided endocarditis. Patients were 102 
followed throughout the duration of antibiotic therapy until 6 weeks after the end of 103 
treatment. A full description of the RCT is available elsewhere [6]. 104 
 105 
Probabilities and duration of study treatment 106 
All effectiveness probabilities used in the model were based on the previous RCT (Table 1), 107 
including the efficacy of the study drugs stratified by type of MRSA infection, the cumulative 108 
incidence of death and the rate of adverse drug reactions (ADR) observed in each study arm. 109 
Data surrounding duration of treatment (days) were obtained from the RCT and then 110 
stratified by mode of administration (oral vs IV). Of note, the overall length of hospital stay 111 
was similar between the two treatment groups [6]. 112 
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 113 
Costs 114 
In this analysis, we used only direct costs in 2016 Swiss francs (CHF) and Euro (€) (1CHF = 115 
0.92€, December 2016) for the study drugs and ADR costs (Appendix 1). Drug costs were 116 
obtained from the Swiss medicines agency (Table 1). In the base case the highest unit price 117 
was used where there was variation due to packaging or volume. For the studied antibiotic 118 
drug, no discount was offered to our institution, so none were considered in the base case 119 
scenario. Equipment costs were added for therapeutic intravenous administration and those 120 
needed for ADR treatment. ADR-related costs also included those pertaining to the lab 121 
testing required for investigation as well the additional therapeutic treatment. The costs of 122 
the laboratory tests were attributed according to the price charged to Geneva University 123 
Hospitals (adjusted to December 2016). In the base case, no ADR-related supplementary 124 
medical exams or hospital stay extensions were costed in, as per the findings of the RCT. 125 
 126 
Quality-adjusted life year 127 
The effectiveness outcome from our model was quality-adjusted life years (QALY; Table 1). 128 
This is a generic measure of disease burden (including quality and quantity of life lived), 129 
which is commonly used in health economics. QALYs are estimated by applying utility 130 
weights that typically range from 0 (death) to 1 (perfect health). In this study we attributed a 131 
utility weight of 1 if the patient fully recovered and 0 if the patient died. In the case of 132 
treatment failure without death, we attributed a utility weight according to the severity of 133 
MRSA infection [8]. The categories of MRSA infection (severe, associated with deep-seated 134 
foci, or non-severe) were determined by site of infection and duration of therapy, as defined 135 
in the RCT [6]. The utility weights attributed to each type of infection were derived from the 136 
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Health-Related Quality-of-Life (HQORL) score using the EuroQol 5D Health Domains (with 137 
United Kingdom scoring) [9, 10]. The QALY was calculated by multiplying weights by average 138 
duration of MRSA infection in the RCT (7/8 days for non-severe-infections, 13/13 days for 139 
severe infections and 30/38 days for infections associated with deep-seated foci, for LZD and 140 
TMP-SMX + RMP, respectively [6]). The same procedure was performed to attribute QALYs 141 
to patients who developed an ADR.  142 
 143 
Cost-effectiveness analysis 144 
We conducted a cost-effectiveness analysis (CEA) - more specifically a cost-utility analysis –145 
to compare the two interventions utilizing a decision tree. The base case scenario was 146 
defined by the following: 147 
Incremental cost (€) = TMP-SMX plus RMP cost - LZD cost 148 
Incremental effectiveness (QALYs) = TMP-SMX plus RMP effectiveness - LZD effectiveness 149 
The incremental cost-effectiveness ratio (ICER) is the ratio of these two values. A strategy is 150 
considered as dominant if it is both less expensive and more effective. 151 
 152 
One-, two- and three-way sensitivity analyses 153 
Sensitivity analyses were conducted to test how variation in one, two, or three variables 154 
could affect model results.  Several key parameters, including LZD efficacy (stratified also by 155 
type of MRSA infection), ADR cost and LZD drug price were altered to capture potential 156 
differences in a real-world setting (see below for full list). 157 
 158 
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Probabilistic sensitivity analysis 159 
We also conducted a probabilistic sensitivity analysis utilizing Monte Carlo (MC) simulation 160 
in order to allow for simultaneous variation of all variables [11], each assigned an 161 
appropriate type of probability distribution according to the type of uncertainty the variable 162 
represents. We performed a MC simulation to sample randomly from those distributions, 163 
comparing possible ICERs over 10’000 iterations. The 95% confidence ellipse was obtained to 164 
create an incremental cost-effectiveness plane in order to facilitate interpretation of the 165 
results. Cost-effectiveness acceptability curves (CEAC) were also calculated to summarize 166 
information and support decision-making under differing perceptions of potential risk and 167 
benefits. 168 
 169 
Generic linezolid cost 170 
As generic LZD was made available in several European countries in 2016, we modelled the 171 
cost-effectiveness using several potential whole-sale prices of generic LZD. According to the 172 
Swiss regulatory authorities, the generic LZD price is permitted to be 10-60% less expensive 173 
than the originator LZD price, depending on sales volume [12]. Recently, the price of 174 
linezolid was fixed in Switzerland with a 10% discount compared to the originator. However, 175 
the reduction can be as much as 50%, as proposed in Italy and Germany. We performed a 176 
sensitivity analysis altering the LZD generic price in line with the different possible price 177 
levels.  178 
 179 
Linezolid efficacy 180 
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Several RCTs on LZD efficacy to treat MRSA infection have already been published. A 181 
literature review was therefore performed utilizing each of these studies in order to extract 182 
the various efficacy levels of LZD in treating MRSA infection (Appendix 2). Twenty different 183 
trials were identified, with a LZD efficacy against MRSA infection ranging from 37% to 100%, 184 
with a median of 75% and a weighted average of 69% (weighted by the number of patients 185 
included in the study). The range of values and the weighted average retrieved from the 186 
literature was incorporated within a triangular distribution in the sensitivity analysis to allow 187 
for variation.  188 
 189 
Serious adverse drug reactions 190 
Due to the relatively small patient sample size in our RCT, rare and serious ADR due to TMP-191 
SMX plus RMP treatment did not occur during our study and were thus not accounted for in 192 
the base case. However, as some types of serious ADR can be extremely expensive and could 193 
increase the cost of treatment per patient, the risk of such occurrences could not be ignored. 194 
After a thorough literature review, including the official prescribing manuals and the 195 
pharmaco-vigilance reference standards, a number of previously described serious ADRs 196 
appeared relevant and were added to the CEA, including Toxic Epidermal Necrolysis (TEN) 197 
and acute renal failure necessitating dialysis (both deriving from TMP-SMX consumption) 198 
and acute liver failure requiring liver transplant (deriving from RMP consumption), among 199 
others (Appendix 3). QALYs were constructed for these serious ADR using data from the 200 
published literature.  201 
 202 
RESULTS  203 
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The base case suggested that, on average, the combination treatment of TMP-SMX plus RMP 204 
(146€ and 0.916 QALY) was less costly and slightly more effective than LZD for treatment of 205 
MRSA infection (2536€, 0.881 QALY). TMP-SMX plus RMP dominated LZD in the treatment of 206 
MRSA infection, with an average cost by one QALY gain of 160€ compared to 2877€ (Table 207 
2).  Stratified by type of MRSA infection (respectively, non-severe, severe or deep-seated 208 
infection), the average cost-effectiveness ratios were 44, 115 and 477€/QALY for TMP-SMX 209 
plus RMP versus 1348, 2595 and 6105 €/QALY for LZD. Results of the simulation suggest that 210 
with a willingness-to-pay threshold of 0€, 50’000€ and 200’000€, TMP-SMX plus RMP was 211 
dominant in 100%, 82% and 73% of the time (Figure 2). Appendix 4 shows the results of the 212 
MC simulation by type of infection. 213 
One- and two-way sensitivity analyses showed that TMP-SMX plus RMP dominated LZD even 214 
when we used extreme scenarios such as a LZD efficacy fixed at 1.0, a maximum assumed 215 
ADR cost attributed to TMP-SMX plus RMP (320€ per patient), or the highest possible 216 
discount offered on the LZD price of 60% (Figure 3). Results of the one-way sensitivity 217 
analysis suggested that a 95% discount on the price of LZD would need to be applied for it to 218 
become more cost-effective than TMP-SMX plus RMP.  219 
These results were confirmed by the three-way sensitivity analysis. The treatment of TMP-220 
SMX plus RMP stayed dominant in each case (Appendix 4). When we performed probabilistic 221 
sensitivity analyses (MC simulations) to reproduce CEACs, with maximum assumed ADR costs 222 
attributed to TMP-SMX plus RMP, varied LZD efficacy and varied LZD prices, results 223 
suggested TMP-SMX plus RMP to be dominant over LZD (Table 4.B.). Even when utilizing an 224 
extreme willingness-to-pay of 200’000€ per QALY gained, the TMP-SMX & RMP regimen 225 
remained dominant in over 77% of cases, with a 50% discount on LZD prices.  226 
 227 
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DISCUSSION 228 
We previously showed in a RCT that anti-MRSA therapy with a combination of older 229 
antibiotics (TMP-SMX plus RMP) is non-inferior to LZD in terms of efficacy and safety [6]. The 230 
use of one versus two independently marketed antibiotics and new versus old antibiotics can 231 
generate cost differences. In an effort to investigate various health-economic scenarios 232 
linked to the use of TMP-SMX plus RMP versus LZD for the treatment of MRSA infection, we 233 
conducted a CEA whose principal findings were: (i) in the base case scenario the combined 234 
treatment of TMP-SMX plus RMP is dominant and more cost-effective compared to LZD, also 235 
considering different types of MRSA infection; (ii) this result is confirmed by probabilistic 236 
sensitivity analyses using MC simulation, in which the combination of the older drugs is 237 
dominant in the vast majority of iterations; (iii) even in extreme scenarios with substantial 238 
discount rates applied to LZD prices and assumed high costs of ADRs for TMP-SMX plus RMP 239 
treatment, the combined treatment using the older antibiotics remains dominant.  240 
 With the emergence of intermediate resistance against vancomycin or LZD [13], 241 
the use of older antibiotics such as TMP-SMX plus RMP could be an interesting and effective 242 
strategy to cure MRSA infection [1, 4, 5]. Moreover, with the increasing incidence of 243 
community-associated MRSA and knowing that these strains are often more susceptible 244 
than healthcare-associated MRSA, in particular to the older antibiotics [14, 15], the use of 245 
TMP-SMX could be considered a suitable alternative treatment strategy. In addition, the oral 246 
administration of these older drugs can reduce the intra-hospital costs by enabling a faster 247 
discharge.  248 
 Several industry-sponsored CEAs have been conducted for LZD. Most of them 249 
showed that, compared to vancomycin, LZD is the more cost-effective strategy in the 250 
treatment of MRSA infection due to earlier discharge from hospital [16-23]. In contrast, our 251 
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analysis shows that with a willingness-to-pay of 50’000€ per QALY gained - a commonly used 252 
threshold for determining value-for-money of new healthcare interventions [24] - a strategy 253 
of using a combination of older drugs such as TMP-SMX & RMP is more cost-effective than 254 
LZD. However, despite the fact that this combination therapy appears very attractive, a 255 
potential limitation could be the lower compliance among patients, which could slightly 256 
decrease efficacy. Indeed number of drugs and frequency of administration can affect 257 
compliance [25, 26].  258 
 A key strength of this work lies in the fact that it is the first industry-independent 259 
study evaluating the economic impact of these two anti-MRSA regimens. The randomized-260 
controlled design allows for high-quality analyses, especially with regard to relative 261 
effectiveness. Moreover, the use of QALYs as the effectiveness measure takes into account 262 
both therapeutic efficacy as well as the potential adverse effects of the different treatments 263 
studied. We performed several sensitivity analyses, which showed stable and robust results, 264 
suggesting with high probability that our findings are applicable to many different clinical 265 
and health-economic settings. Finally, with a sensitivity analysis performed on potential 266 
discounts to simulate alternative LZD prices, this study suggests that generic LZD is still not 267 
cost-effective in Switzerland or Germany, and allows for future comparisons between the 268 
older treatment combination and the generic equivalent of LZD in other countries. 269 
 Our analysis has some limitations. First, the RCT was confined to a selected 270 
population from a single hospital in Switzerland with a specific endemic MRSA strain [27], 271 
possibly limiting the external validity of the trial results. Second, the sample size of this RCT 272 
was too small to capture all potential treatment-related ADRs that may occur. We therefore 273 
had to simulate the financial impact of missing ADRs and related health-economic adverse 274 
outcomes in the CEA. Consequently, we chose to conservatively overestimate ADR 275 
incidence, largely increasing the potential ADR costs for the old combined antibiotics. The 276 
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costs were derived from an average of DRG costs charged to patients presenting similar 277 
pathologies at the Geneva University Hospitals. For a few rare pathologies (e.g., Stevens-278 
Johnson Syndrome), the averages were generated from a small number of episodes, making 279 
them potentially less representative. Finally, whereas an itemized, franc per franc cost 280 
structure was assumed in this study, in reality bundling and profit-seeking on the part of the 281 
hospital (reimbursement claims exceeding expense) may distort some costs. 282 
In conclusion, the result of our analysis suggests that, on cost-effectiveness grounds, 283 
treatment with TMP-SMX plus RMP is more cost-effective than LZD for the treatment of 284 
MRSA infection from the perspective of the health-care system. 285 
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Figure Legends 311 
 312 
Figure 1. Decision tree model. 313 
LZD, linezolid; TMP-SMX, trimethoprim-sulfamethoxazole; RMP, rifampicin; ADR, adverse 314 
drug reaction; MRSA, methicillin-resistant Staphylococcus aureus.  315 
 316 
Figure 2. Incremental cost-effectiveness plane and table, with cost-effectiveness 317 
acceptability curves (CEAC) 318 
LZD: linezolid; Incr. Cost: incremental cost; Incr. Eff: incremental effectiveness; Incr. cost-319 
Effect.: Incremental cost-effectiveness; QALYs: quality-adjusted life years; RMP: rifampicin; 320 
TMP-SMX: trimethoprim-sulfamethoxazole 321 
A. Monte Carlo simulation. Each blue spot represents one of the 10’000 iterations. The two 322 
orange lines represent the base-case scenario.  323 
B. Cost-effectiveness acceptability curves 324 
 325 
Figure 3. One-Way and Two-Way sensitivity analysis on assumed inputs 326 
ADR: adverse drug reaction; LZD: linezolid; QALYs: quality-adjusted life years; RMP: 327 
rifampicin; TMP-SMX: trimethoprim-sulfamethoxazole 328 
A. One-way sensitivity graph: the cost by QALY gained is represented for each treatment 329 
according to the value for the variable tested.  330 
B. Two-way sensitivity analysis is an analysis in which two variables of interest are 331 
simultaneously varied over a range of plausible values while holding all other variables 332 
constant (according to the base case scenario). In these types of graphs the most cost-333 
effective interventions according to the value for the variables tested are represented 334 
according to their colors (TMP-SMX + RMP: light blue, LZD: dark blue). 335 
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The orange line represents the 10% discount on generic LZD price applied in Switzerland 336 
since late 2016. 337 
 338 
  339 
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Appendix 1. Adverse Drug Reaction costs during the RCT 
 
 
Case Group of treatment Type Treatment administered Laboratory test Costs 
   Name Administration Dosage Number Type Number  
1 TMP-SMX + RMP Neurological Ø Ø 0€ 
2 LZD Tongue discoloration 
 
Ø Ø 0€ 
3 TMP-SMX + RMP Dermatological clemastine fumarate IV 2mg 2 Ø 7.11€ 
prednisone PO 20mg 2 
4 TMP-SMX + RMP Gastrointestinal metoclopramid PO 10mg 1 Ø 39.31€ 
ondansetron PO 8mg 4 
domperidone PO 10mg 2 
5 LZD Nephrological NaCl IV 0.9% - 1.5l 1 creatinine 3 31.19€ 
urea 3 
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LZD: linezolid; PO: per os; RMP: rifampicin; TMP-SMX: trimethoprim-sulfamethoxazole; IV: intraveinous 
  
6 TMP-SMX + RMP Nephrological ø Ø 0€ 
7 LZD Haematological ø Ø 0€ 
8 TMP-SMX + RMP Gastrointestinal domperidone PO 10mg 1 Ø 0.44€ 
9 TMP-SMX + RMP Dermatological clemastine fumarate IV 2mg 4 Ø 12.47€ 
10 LZD Gastrointestinal domperidone PO 10mg 1 Ø 5.91€ 
ondansetron PO 4mg 1 
11 TMP-SMX + RMP Gastrointestinal domperidone PO 10mg 2 pregnancy test 1 22.43€ 
ondansetron PO 4mg 1 
12 TMP-SMX + RMP Nephrological ø Ø 0€ 
13 TMP-SMX + RMP Gastrointestinal ondansetron PO 8mg 3 Ø 50.56€ 
 ondansetron PO 4mg 4 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
Appendix 2. Literature Review on the Efficacy of LZD to treat MRSA infection, generated by RCTs 
Author Year Title 
n 
(success) 
Total N 
Linezolid 
efficacy (%) 
Rubinstein [1] 2001 
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with 
nosocomial pneumonia: a randomized, double-blind, multicenter study. 
15 23 0.65 
Stevens [2] 2002 
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus 
aureus infections. 
59 98 0.60 
Wible [3] 2003 
Linezolid versus cefadroxil in the treatment of skin and skin structure infections in 
children. 
13 14 0.93 
Kaplan [4] 2003 
Linezolid versus vancomycin for treatment of resistant Gram-positive infections in 
children. 
15 18 0.83 
Yogev [5] 2003 Linezolid for the treatment of complicated skin and skin structure infections in children. 9 10 0.90 
Wunderink [6] 2003 
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-
resistant Staphylococcus aureus nosocomial pneumonia. 
36 75 0.48 
Lipsky [7] 2004 Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of 13 18 0.72 
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linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. 
Weigelt [8] 2004 Linezolid eradicates MRSA better than vancomycin from surgical-site infections. 26 30 0.87 
Sharpe [9] 2005 
Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the 
treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by 
methicillin-resistant Staphylococcus aureus. 
15 30 0.50 
Weigelt [10] 2005 Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. 125 176 0.71 
Kohno [11] 2007 
Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant 
Staphylococcus aureus in Japan. 
22 60 0.37 
Wunderink [12] 2008 
Early microbiological response to linezolid vs vancomycin in ventilator-associated 
pneumonia due to methicillin-resistant Staphylococcus aureus. 
13 23 0.57 
Wilcox [13] 2009 
Complicated skin and skin-structure infections and catheter-related bloodstream 
infections: noninferiority of linezolid in a phase 3 study. 
42 48 0.88 
Itani [14] 2010 
Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin 
and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus 
aureus. 
223 276 0.81 
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Craft [15] 2011 
A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral 
fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin 
and skin structure infections. 
37 37 1.0 
Covington [16] 2011 
Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability 
and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of 
acute bacterial skin and skin structure infection. 
25 29 0.86 
Wunderink [17] 2012 
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a 
randomized, controlled study. 
102 186 0.55 
Noel [18] 2012 
A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of 
omadacycline to those of linezolid for treatment of complicated skin and skin structure 
infections. 
30 32 0.94 
Prokocimer [19] 2013 
Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure 
infections: the ESTABLISH-1 randomized trial. 
77 90 0.86 
Chavanet [20] 2013 
The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA 
pneumonia. 
95 165 0.58 
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Harbarth [21] 2015 
Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus 
rifampicin versus linezolid for the treatment of MRSA infection. 
56 75 0.75 
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Appendix 3. Serious Adverse Drug Reaction simulation 
ADR: adverse drug reaction; LZD: linezolid; QALYs: quality-adjusted life years; RMP: rifampicin; TMP-SMX: trimethoprim-sulfamethoxazole 
a Average cost charged at Geneva University Hospitals in 2015  
b Real incidence is unknown, the maximum incidence found in the Swiss drug information has been applied 
  
Treatment Type of ADR Incidence maximum Cost by ADR  Average cost by patient 
treated by the study drug 
QALYs 
RMP Liver failure requiring liver 
transplant 
Rare 
1/1000b  
190’000CHF/174’632€a 
 
190CHF/178€ 0.69 [22] 
TMP-SMX Lyell, Stevens-Johnson syndrome Very rare  
1/10’000b 
32’000CHF/29411€a 3CHF/3€ 0.66 [23] 
TMP-SMX Renal failure with dialysis Very rare 
1/10’000b 
70’000CHF/64338€/yeara 
(Average duration, 21 years) 
140CHF/135€ 0.70 [24] 
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Appendix 4. Incremental cost-effectiveness plane and table, cost-effectiveness 
acceptability curves (CEAC) by type of infection 
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LZD: linezolid; Incr. Cost: incremental cost; Incr. Eff: incremental effectiveness; Incr. cost-
Effect.: Incremental cost-effectiveness; QALYs: quality-adjusted life years; RMP: rifampicin; 
TMP-SMX: trimethoprim-sulfamethoxazole 
A. Monte Carlo simulation. Each blue spot represents one of the 10’000 iterations. The two 
orange lines represent the base-case scenario. B. Cost-effectiveness acceptability curves 
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Appendix 5. Three-way sensitivity analysis and cost-effectiveness acceptability curves 
(CEAC) on assumed inputs, considering various discounted pricing of generic linezolid 
 
 
ADR: adverse drug reaction; LZD: linezolid; RMP: rifampicin; TMP-SMX: trimethoprim-
sulfamethoxazole 
A. Three-way sensitivity analysis is an analysis in which two variables of interest are 
simultaneously varied over a range of plausible values while holding a third variable with a 
determinate value and all other variables constant (according to the base case scenario). In 
these types of graphs the most cost-effective intervention according to the value for the 
variables tested is represented according to their colors. B. Cost-effectiveness acceptability 
curves.  
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Table 1. Model Input Data for the Base-Case Scenario 
ADR: adverse drug reaction; Distrib.: Distribution; LZD: linezolid; PO: per os; QALYs: quality-
adjusted life years; Ref.: References; RMP: rifampicin; TMP-SMX: trimethoprim-
sulfamethoxazole; IV: intravenous 
a
 Costs are adjusted to December 2016  
Variables 
Non-severe 
infections 
(N=62) 
Severe 
infections 
(N=53) 
Infection 
associated 
with deep-
seated foci 
(N=35) 
 
Ref. 
Probabilities Mean SD Mean SD Mean SD Distrib.
a
 
LZD Treatment (N=75) 0.36 0.06 0.41 0.06 0.23 0.05 Beta [6] 
     Presence of ADR 0.04 0.04 0.13 0.06 0.00 0.00 Beta [6] 
     Treatment failure 0.19 0.07 0.29 0.08 0.29 0.11 Beta [6] 
          Death among  treatment failure 0.00 0.00 0.67 0.16 0.40 0.22 Beta [6] 
TMP-SMX + RMP Treatment  (N=75) 0.47 0.06 0.29 0.05 0.24 0.05 Beta [6] 
     Presence of ADR 0.14 0.06 0.06 0.04 0.06 0.05 Beta [6] 
     Treatment failure 0.14 0.06 0.23 0.09 0.33 0.11 Beta [6] 
          Death among  treatment failure 0.00 0.00 0.60 0.22 0.33 0.19 Beta [6] 
Durations of treatment (days) Mean SD Mean SD Mean SD Distrib.
a
 
LZD Treatment (N=75)        
     IV administration  0.63 1.84 0.97 2.95 1.65 3.46 Gamma [6] 
     PO  administration   7.11 3.37 10.98 4.56 28.71 10.74 Gamma [6] 
TMP-SMX + RMP Treatment  (N=75)        
     IV  administration 0.03 0.17 0.73 2.98 4.83 9.86 Gamma [6] 
     PO  administration 7.89 2.18 12.00 4.27 32.28 28.64 Gamma [6] 
Costs  Price, by drug unit,
b
 CHF/€  
LZD IV treatment (600mg) 92.23 / 84.77  
c 
LZD PO treatment (600mg)  94.14 / 86.53  
c
 
TMP-SMX IV treatment (800/160mg) 5.08 / 4.67  
c
 
TMP-SMX PO treatment (800/160mg) 0.67 / 0.62  
c
 
RMP PO treatment (600mg) 3.48 / 3.20  
c
 
RMP IV treatment (600mg) 37.60 / 34.56  
c
 
ADR due to LZD treatment (mean) 0.00 / 0.00 10.09 / 9.27 0.00 / 0.00  
c
 
ADR due to TMP-SMX + RMP treatment (mean) 20.24 / 18.60 0.00 / 0.00 42.77 / 39.31  
c
 
IV material by days of treatment 1.44 / 1.32  
d 
QALYs  
Death 0.00 0.00 0.00  [8, 9, 10] 
Cure 1.00 1.00 1.00  [8, 9, 10] 
No cure    
     LZD 0.96 0.90 0.86  [8, 9, 10] 
     TMP-SMX + RMP 0.95 0.89 0.82  [8, 9, 10] 
ADR 0.00 0.00 0.00  [8, 9, 10] 
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b
  We used a beta distribution, a continuous probability distribution defined on the interval 
[0, 1], for the following variables: efficacy of the study drugs, cumulative incidence of death 
and ADR. All variables surrounding duration of treatment were assumed to follow a gamma 
distribution, due to their continuous nature. 
c 
http://www.listedesspecialites.ch/ Federal Department of Home Affairs - Federal Office of 
Public Health - List of specialties [cited 2016 December]. 
d 
The price of this kit is 5.75 CHF, provided by the pharmacy of the Geneva University 
Hospitals. According to the local recommendations, the peripheral venous catheter has to be 
changed every 4 days, representing a daily price of this supply for intravenous administration 
of 1.44 CHF. 
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Table 2. Base case scenario by type of MRSA infection 
 
 
 
 
 
 
 
 
 
ACER: Average cost-effectiveness ratio; ICER: Incremental cost-effectiveness ratio; LZD: linezolid; RMP: rifampicin; TMP-SMX: trimethoprim-
sulfamethoxazole 
 
 
 
Any type of 
infection 
Non-severe 
infections 
Severe infections Infections associated with deep-seated foci 
     
TMP-SMX + RMP treatment     
• Cost 146.23€ 43.91€ 96.96€ 406.16€ 
• effectiveness (QALY) 0.916 0.993 0.846 0.851 
• ACER (€/QALY) 159.59 44.22 114.63 477.10 
     
LZD treatment     
• Cost 2535.75€ 1337.70€ 2066.16€ 5248.04€ 
• Effectiveness, (QALY) 0.881 0.992 0.796 0.860 
• ACER (€/QALY) 2876.97  1347.94 2595.26 6104.93 
     
Incremental cost -2389.51€ -1293.79€ -1969.20€ -4841.88€ 
Incremental effectiveness (QALY) 0.035 0.001 0.050 -0.008 
ICER (€/QALY) Dominant Dominant Dominant 631883 
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A.	
B.	
Quadrant Incr. Cost 
(€) 
Incr. Effect. 
(QALY) 
Incr. 
Cost-Effect. 
Freq. Prop. 
North-East IC>0.0 IE>0.0 ICER>0.0 1 0% 
North-West IC<0.0 IE>0.0 Dominated 1 0% 
South-West IC<0.0 IE<0.0 ICER>0.0 2227 22% 
South-East IC>0.0 IE<0.0 Dominant 7771 78% 
Any type of infection 
Any type of infection 
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